Skip to main content
OpenTrials
Completed

NCT Number: NCT01169792

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen.

The investigators want to

* evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and * analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Neoplasms Antineoplastic Agents Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases Survival Analysis Therapeutic Uses

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Jin-Gu, Busan, South Korea

Loading trial locations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age ≥ 18 years
  • Breast cancer patients who underwent surgery

Exclusion criteria

  • None

Treatment and study plan

Tamoxifen

Drug

Primary outcomes

  1. The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients

  2. The frequency of the genetic polymorphisms of CYP3A4/5 in breast cancer patients

  3. The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients

Secondary outcomes

  1. The association between the genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen therapy

  2. The association between the genetic polymorphisms of CYP3A4/5 and outcomes in breast cancer patients with tamoxifen therapy

  3. The association between the genetic polymorphisms of CYP2C19 and outcomes in breast cancer patients with tamoxifen therapy

Sponsors and collaborators

Lead sponsor

Yonsei University

Other

Collaborators

  • Inje University

Registry information

Official study title

Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment

Important dates

First posted
Jul 26, 2010
Registry last updated
Jul 26, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.